Tech Company Financing Transactions
Presidio Pharmaceuticals Funding Round
Presidio Pharmaceuticals closed a $21.8 million Series D investment round on 6/16/2014. Investors included private investors.
Transaction Overview
Company Name
Announced On
6/16/2014
Transaction Type
Venture Equity
Amount
$21,827,981
Round
Series D
Investors
Proceeds Purpose
Proceeds purposes were not disclosed. SEC regulatory filing. Contact technology company for investment details, if applicable. Not an offer or solicitation for sale of securities.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
1700 Owens St. 184
San Francisco, CA 94158
USA
San Francisco, CA 94158
USA
Phone
Website
Email Address
Overview
Presidio is focused on developing novel and established therapeutic modalities and small molecule compounds for the treatment of HIV-1, HCV and other chronic virus infections.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Financial Officer
Leo Redmond
Chief Medical Officer
Nathaniel Brown
Chief Scientific Officer
Richard Colonno
VP - Regulatory Affairs
Eric Ruby
Browse more venture capital transactions:
Prev: 6/16/2014: Groundfloor venture capital transaction
Next: 6/16/2014: Plasmonix venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. All VC database entries reported here are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs